The global non-invasive prenatal testing (NIPT) market is expected to grow at a 16.35% CAGR during the forecast period 2021-2027 and will reach USD 6.23 billion by 2027.
Factors attributing to the growth of non-invasive prenatal testing market include increased risk of chromosomal abnormalities with rising maternal age, surge in occurrences of chromosomal aneuploidies in fetus, rising awareness of non-invasive techniques over conventional invasive methods and mounting prominence of genetic and congenital disorders, thereby proliferating the growth of the non-invasive prenatal testing market.
Furthermore, development of cutting-edge non-invasive prenatal testing products, rising focus of early detection and prevention, and growth in reimbursement policies towards more genetic coverage will accelerate the market development of NIPT industry.
Request to get a free sample copy of this research report with detailed TOC at https://www.vynzresearch.com/healthcare/non-invasive-prenatal-testing-market/request-sample
The COVID-19 outbreak will have an impact on the non-invasive prenatal testing industry as several non-invasive prenatal screening services were put on hold and hospitals & diagnostic centers were offering services to COVID-19 patients.
However, lockdown restrictions amidst COVID-19 crisis have also brought NIPT to the forefront, as it provides high accuracy screening with a low risk of infection, as opposed to invasive procedures such as amniocentesis and chorionic villus sampling (CVS), both of which may require hospitalization, exposing both doctors and patients to the risk of COVID infection.
- Next-Generation Sequencing Systems
- Ultrasound Devices
- Polymerase Chain Reaction Instruments
- Assay Kits & Reagents
Consumable segment holds a largest share in the NIPT industry owing to the increased number of lab-based tests performed worldwide, rising incidences of chromosomal abnormalities, introduction of novel test kits by industry players, and rising research and development activities for screen genetic disorders, thereby propelling the market development of the consumables segment in NIPT industry.
- Cell-Free DNA in Maternal Plasma Tests
- Ultrasound Detection
- Fetal Cell in Maternal Blood Tests
- Biochemical Screening Tests
Cell-Free DNA in Maternal Plasma Tests will hold significant share during the forecast period as they are deployed to determine the risk of genetic conditions in prenatal care. Ultrasound detection is used as a complement to the Cell-free DNA-based NIPT test, resulting in a lower market share for this segment. Nevertheless, the test provides a foundation for further testing of the fetus to identify abnormalities. Recent technological advancements and 3D-4D imaging have enhanced real-time monitoring, safety, and efficacy of the test, which is expected to drive segment growth further.
- Microdeletion Syndrome
Trisomy is a type of chromosomal abnormality in which an individual has three copies of one chromosome rather than two as is the norm. Trisomy contributes the largest share in the market owing to rising maternal age and increased number of chromosomal abnormalities. With the successful integration of NIPT into normal prenatal care for the identification of Trisome, it is essential to understand the risks, advantages, and limitations so that patients can make an informed decision. As a result, demand for these technologies has surged, and many emerging countries are adopting them, potentially driving the segment's growth.
- Diagnostic Laboratories
Diagnostic laboratories contribute the largest share in the non-invasive prenatal testing market. Owing to the availability of well-equipped facilities and trained/skilled laboratory technicians, a greater volume of tests are being outsourced to diagnostic labs, driving a larger share of this segment. Furthermore, the growing number of initiatives undertaken by diagnostic laboratories to provide safe and effective prenatal tests is projected to support o the NIPT market among diagnostic laboratories over the forecast period.
- North America
- Asia Pacific
- Rest of the World
North America contributes the largest share in the NIPT industry as it has strong economies in the US and Canada along substantial investment in technology. Furthermore, effective reimbursement structure and increased awareness about NIPT, rising demand for early detection of birth defect will fuel the growth of non-invasive prenatal testing industry.
Ask for Customization of this Research Report at https://www.vynzresearch.com/healthcare/non-invasive-prenatal-testing-market/customize-report
In January 2022, QIAgen N.V. unveiled new additions to the growing number of QIAcuity applications, its ultrasensitive digital PCR (dPCR) platform that has established new benchmarks by using so-called nanoplates to process samples in 2 hours rather than the 5 hours required by other systems.
QIAGEN has formed two new partnerships that will help to expand the QIAcuity ecosystem:
- Collaboration with Atila BioSystems, to develop a non-invasive prenatal testing (NIPT) solution for the QIAGEN dPCR franchise. NIPT simply requires blood samples from the mother and replaces more invasive testing methods that can harm the fetus and mother, such as amniocentesis.
- A co-exclusive licensing and co-marketing agreement with German life-sciences start-up Actome GmbH has extended QIAcuity's reach beyond genomics into proteomics which enables the quantification of proteins as well as the analysis of interactions between proteins and target genes.
About VynZ Research:
VynZ Research is a global market research firm offering research, analytics, and consulting services on business strategies. VynZ Research has a recognized trajectory record and our research database is used by many renowned companies and institutions in the world to strategize and revolutionize business opportunities. The company focuses on providing valuable insights on various technology verticals such as Chemicals, Automotive, Transportation, Energy, Consumer Durables, Healthcare, ICT and other emerging technologies.
Toll-Free (U.S. and Canada): +1-888-253-3960
Email: email@example.comTags:PR-Wirein, Extended Distribution, Research Newswire, English